Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares of the company's stock, valued at $10,479,005.02. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

• MarketBeat Week in Review – 4/17 - 4/21

Andrew Guggenhime also recently made the following trade(s):

• On Thursday, July 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $81.17, for a total transaction of $649,360.00.

Vaxcyte Trading Up 0.5 %

Shares of PCVX traded up $0.58 during mid-day trading on Thursday, reaching $117.12. The company's stock had a trading volume of 1,008,071 shares, compared to its average volume of 848,831. The stock has a market cap of $12.74 billion, a P/E ratio of -27.36 and a beta of 0.97. Vaxcyte, Inc. has a 1-year low of $44.20 and a 1-year high of $121.06. The business has a 50-day simple moving average of $87.76 and a two-hundred day simple moving average of $75.76.

• Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.04. During the same quarter in the prior year, the firm earned ($0.70) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -4.33 EPS for the current year.

Wall Street Analyst Weigh In

PCVX has been the topic of several analyst reports. Leerink Partners boosted their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 3rd. Jefferies Financial Group upped their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Bank of America raised their price target on Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Needham & Company LLC upped their price objective on Vaxcyte from $95.00 to $140.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Finally, BTIG Research increased their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $147.50.

• Why Investors Are Suddenly Excited About Vaxcyte

Read Our Latest Stock Analysis on PCVX

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PCVX. Parallel Advisors LLC boosted its holdings in shares of Vaxcyte by 155.3% during the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company's stock worth $26,000 after acquiring an additional 250 shares during the period. Fifth Third Bancorp bought a new stake in Vaxcyte in the 2nd quarter valued at $35,000. Fidelis Capital Partners LLC acquired a new position in Vaxcyte in the 1st quarter valued at $37,000. J.Safra Asset Management Corp increased its position in Vaxcyte by 649.4% during the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock worth $46,000 after buying an additional 526 shares during the period. Finally, Quest Partners LLC acquired a new stake in shares of Vaxcyte during the second quarter worth $70,000. 96.78% of the stock is owned by institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Read More

• Five stocks we like better than Vaxcyte
• How to Use High Beta Stocks to Maximize Your Investing Profits
• Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
• Where Do I Find 52-Week Highs and Lows?
• How the Fed’s Rate Cut Could Supercharge These 3 ETFs
• 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
• Microsoft Stock: 3 Reasons It’s Ready to Crush Q4

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad)

Should you invest $1,000 in Vaxcyte right now?

Before you consider Vaxcyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.

While Vaxcyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here